Antineoplastic effects of liposomal short interfering RNA treatment targeting BLIMP1/PRDM1 in primary effusion lymphoma.

作者信息

Riva Giovanni, Lagreca Ivana, Mattiolo Adriana, Belletti Daniela, Lignitto Laura, Barozzi Patrizia, Ruozi Barbara, Vallerini Daniela, Quadrelli Chiara, Corradini Giorgia, Forghieri Fabio, Marasca Roberto, Narni Franco, Tosi Giovanni, Forni Flavio, Vandelli Maria Angela, Amadori Alberto, Chieco-Bianchi Luigi, Potenza Leonardo, Calabrò Maria Luisa, Luppi Mario

机构信息

Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia; Hematology Unit, AOU Policlinico, Modena, Italy.

Immunology and Molecular Oncology, Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy.

出版信息

Haematologica. 2015 Nov;100(11):e467-70. doi: 10.3324/haematol.2015.126854. Epub 2015 Jul 23.

DOI:10.3324/haematol.2015.126854

PMID:26206802

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4825307/

Abstract

摘要

相似文献

Antineoplastic effects of liposomal short interfering RNA treatment targeting BLIMP1/PRDM1 in primary effusion lymphoma.

Haematologica. 2015 Nov;100(11):e467-70. doi: 10.3324/haematol.2015.126854. Epub 2015 Jul 23.

PEGylated siRNA lipoplexes for silencing of BLIMP-1 in Primary Effusion Lymphoma: In vitro evidences of antitumoral activity.

Eur J Pharm Biopharm. 2016 Feb;99:7-17. doi: 10.1016/j.ejpb.2015.11.007. Epub 2015 Nov 25.

EBV-miR-BHRF1-2 targets PRDM1/Blimp1: potential role in EBV lymphomagenesis.

Leukemia. 2016 Mar;30(3):594-604. doi: 10.1038/leu.2015.285. Epub 2015 Nov 4.

Highly selective fusion and accumulation of hybrid liposomes into primary effusion lymphoma cells along with induction of apoptosis.

Biochem Biophys Res Commun. 2010 Mar 12;393(3):445-8. doi: 10.1016/j.bbrc.2010.02.016. Epub 2010 Feb 6.

In vitro evaluation of optimized liposomes for delivery of small interfering RNA.

J Liposome Res. 2014 Dec;24(4):270-9. doi: 10.3109/08982104.2014.907306. Epub 2014 Apr 8.

Potent reactive oxygen species-JNK-p38 activation by sodium salicylate potentiates death of primary effusion lymphoma cells.

Anticancer Res. 2014 Apr;34(4):1865-71.

HIV protease inhibitor Lopinavir induces apoptosis of primary effusion lymphoma cells via suppression of NF-κB pathway.

Cancer Lett. 2014 Jan 1;342(1):52-9. doi: 10.1016/j.canlet.2013.08.045. Epub 2013 Sep 5.

Cisplatin disrupts the latency of human herpesvirus 8 and induces apoptosis in primary effusion lymphoma cells.

Cancer Invest. 2012 May;30(4):268-74. doi: 10.3109/07357907.2012.657813. Epub 2012 Apr 5.

Validation of telomerase and survivin as anticancer therapeutic targets using ribozymes and small-interfering RNAs.

Methods Mol Biol. 2007;361:239-63. doi: 10.1385/1-59745-208-4:239.

Immunoliposomal systems targeting primary effusion lymphoma: in vitro study.

Nanomedicine (Lond). 2010 Sep;5(7):1051-64. doi: 10.2217/nnm.10.83.

引用本文的文献

Co-Infection of the Epstein-Barr Virus and the Kaposi Sarcoma-Associated Herpesvirus.

Viruses. 2022 Dec 2;14(12):2709. doi: 10.3390/v14122709.

The Role of Coinfections in the EBV-Host Broken Equilibrium.

Viruses. 2021 Jul 19;13(7):1399. doi: 10.3390/v13071399.

Primary effusion lymphoma enhancer connectome links super-enhancers to dependency factors.

Nat Commun. 2020 Dec 9;11(1):6318. doi: 10.1038/s41467-020-20136-w.

Human Herpesvirus 8 and Lymphoproliferative Disorders.

Mediterr J Hematol Infect Dis. 2018 Nov 1;10(1):e2018061. doi: 10.4084/MJHID.2018.061. eCollection 2018.

本文引用的文献

Liposomal siRNA nanocarriers for cancer therapy.

Adv Drug Deliv Rev. 2014 Feb;66:110-6. doi: 10.1016/j.addr.2013.12.008. Epub 2013 Dec 30.

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.

Lancet. 2014 Jan 4;383(9911):60-68. doi: 10.1016/S0140-6736(13)61914-5. Epub 2013 Oct 3.

Safety and efficacy of RNAi therapy for transthyretin amyloidosis.

N Engl J Med. 2013 Aug 29;369(9):819-29. doi: 10.1056/NEJMoa1208760.

Novel polymeric/lipidic hybrid systems (PLHs) for effective Cidofovir delivery: preparation, characterization and comparative in vitro study with polymeric particles and liposomes.

Int J Pharm. 2011 Jul 15;413(1-2):220-8. doi: 10.1016/j.ijpharm.2011.04.025. Epub 2011 Apr 21.

Immunoliposomal systems targeting primary effusion lymphoma: in vitro study.

Nanomedicine (Lond). 2010 Sep;5(7):1051-64. doi: 10.2217/nnm.10.83.

Cidofovir-loaded liposomes: an intro-study using BCBL-1 cell line as a model for primary effusion lymphoma.

Eur J Pharm Sci. 2010 Oct 9;41(2):254-64. doi: 10.1016/j.ejps.2010.06.012. Epub 2010 Jul 1.

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.

Nature. 2010 Apr 15;464(7291):1067-70. doi: 10.1038/nature08956. Epub 2010 Mar 21.

Antineoplastic activity of lentiviral vectors expressing interferon-alpha in a preclinical model of primary effusion lymphoma.

Blood. 2009 May 7;113(19):4525-33. doi: 10.1182/blood-2008-09-180307. Epub 2009 Feb 4.

Knocking down barriers: advances in siRNA delivery.

Nat Rev Drug Discov. 2009 Feb;8(2):129-38. doi: 10.1038/nrd2742.

Induction of apoptosis in plasma cells by B lymphocyte-induced maturation protein-1 knockdown.

Cancer Res. 2007 Dec 15;67(24):11914-23. doi: 10.1158/0008-5472.CAN-07-1868.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验